Indeed, KRAS mutated tumor cells induced stromal cells to secrete IGF1 and GAS6 that in turn activated IGF1R and AXL signaling in tumor cells, leading to increased mitochondrial performance, proliferative capacity, and resistance to apoptotic stimuli [75]. This evidence concerns the gene KRAS and neoplasm.